ERN1 and scleroderma: Our finding that pharmacological inhibition of IRE1α could revert the profibrotic phenotype of activated myofibroblasts isolated from patients with scleroderma indicates that ER stress inhibitors should be taken into consideration when developing new strategies for the treatment of fibrotic diseases.